This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
TLDR Biotech
The top stories in biotech & pharma, straight to your inbox in only one email.Trusted by 2700+ biotech and pharma professionals.
I consent to receive newsletters via email. Terms of use and Privacy policy.
Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.
Apr 22, 2026
•
3 min read
🧬 Ray Therapeutics raises $125M Series B for genetic retinal degeneration gene therapy, Flagship Pioneering launches Serif Biomedicines with $50M to develop novel modified DNA genetic medicines, AstraZeneca's Ultomiris (ravulizumab) meets primary endpoint in Ph3 trial for immunoglobulin A nephropathy, Merck & Co.'s Idvynso (doravirine/islatravir) wins FDA approval for virologically suppressed adults with human immunodeficiency virus following Ph3 success
Apr 21, 2026
4 min read
🧬 Eli Lilly acquires Kelonia Therapeutics for up to $7B to expand in vivo CAR-T capabilities, AstraZeneca's (tozorakimab) meets primary endpoint in Ph3 trial for chronic obstructive pulmonary disease, Biogen + TJ Biopharma expand partnership for China rights to felzartamab - $100M upfront + $850M biobucks
Apr 20, 2026
🧬 Former Genentech leader unveils Synthetic Design Lab - developing adaptive "smart" ADC cancer drugs, UCB to acquire Neurona Therapeutics for up to $1.2B - expanding into seizure cell therapy, Merck & Co. unveils Ph1/Ph2 data for MK-2010 (MK-2010) - PD-1xVEGF bispecific in non-small cell lung cancer
Apr 18, 2026
🧬 From policy to production: how China is scaling synthetic biology - and what it means for global competition
Apr 17, 2026
🧬 Kailera Therapeutics prices massive $625M IPO for advancing next-generation obesity care treatments, Roche launches new Phase III study to pursue EU approval for DMD gene therapy Elevidys, Aligos Therapeutics + Amoytop ink $445M deal licensing HBV drug pevifoscorvir sodium China rights
Apr 16, 2026
🧬 Spain plans $200M VC fund bridging Spanish biotechs with Boston's life science ecosystem, Beeline Medicines debuts with $300M Series A - licensing five Bristol Myers immune disease drug candidates, Sandoz signs manufacturing and supply agreement with Rwanda government to provide critical medicines across Africa
Apr 15, 2026
8 min read
🧬 Novo Nordisk + OpenAI partner to integrate AI across drug discovery + manufacturing + corporate operations, Amazon Web Services launches Amazon Bio Discovery AI tool to accelerate antibody design and drug discovery, Eli Lilly acquires CrossBridge Bio for up to $300M to advance dual-payload ADC cancer pipeline, Alamar Biosciences files for $159M IPO - protein sequencing and biomarker profiling tools, Harbinger Health raises $100M to develop RESOLVE multi-cancer liquid biopsy detection tests
Apr 14, 2026
🧬 Kailera plans $528.5M IPO to advance quartet of Chinese obesity assets, Eli Lilly's Jaypirca hits Ph3 endpoint for chronic lymphocytic leukemia in fixed-duration combination therapy, AbbVie + Haisco Pharmaceutical partner on pain compounds development - up to $715M deal value
Apr 13, 2026
7 min read
🧬 Sun Pharma readies $12B binding offer to acquire women's health company Organon amid competing bids, Vivatides Therapeutics raises $54M Series A for RNA delivery beyond the liver, GSK advances mocertatug rezetecan (Mo-Rez) targeting B7-H4 to Ph3 trials for ovarian and endometrial cancers